Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
Calcified Tissue International|September 9, 2025
X-Linked Hypophosphatemia: Role of Fibroblast Growth Factor 23 on Human Skeletal Muscle-Derived CellsI Falsetti, G Palmini, S Donati, et al.
Journal of Neurology|January 25, 2025
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE studyPiero Barbanti, Cinzia Aurilia, Paola Torelli, et al.
Biology|July 2, 2021
Human Trisomic iPSCs from Down Syndrome Fibroblasts Manifest Mitochondrial Alterations Early during Neuronal DifferentiationNunzia Mollo, Matteo Esposito, Miriam Aurilia, et al.
Trials|July 27, 2021
Effects of early respiratory physiotherapy on spontaneous respiratory activity of preterm infants: study protocol for a randomized controlled trialAlessia Di Polito, Arianna Del Vecchio, Milena Tana, et al.
European Journal of Neurology|September 13, 2022
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT studyFabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
The Journal of Headache and Pain|September 12, 2018
Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaireAlberto Raggi, Venusia Covelli, Erika Guastafierro, et al.
Journal of the American Society of Nephrology : JASN|December 4, 2024
TRPML-1 Dysfunction and Renal Tubulopathy in Mucolipidosis Type IVGiuseppina Grieco, Sandro Montefusco, Edoardo Nusco, et al.
Journal of the American Society of Nephrology : JASN|April 1, 2025
TRPML-1 Dysfunction and Renal Tubulopathy in Mucolipidosis Type IVGiuseppina Grieco, Sandro Montefusco, Edoardo Nusco, et al.
The Journal of Headache and Pain|November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patientsPiero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain|May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Pageof 16